Advances in Heart Failure

Cancer Therapy–Related Cardiac Dysfunction and Heart Failure
Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging

Michelle W. Bloom, MD; Carine E. Hamo, MD; Daniela Cardinale, MD, PhD; Bonnie Ky, MD, MSCE; Anju Nohria, MD; Lea Baer, MD; Hal Skopicki, MD, PhD; Daniel J. Lenihan, MD; Mihai Gheorghiade, MD; Alexander R. Lyon, MD, PhD; Javed Butler, MD MPH MBA

Abstract—Advances in cancer therapy have resulted in significant improvement in long-term survival for many types of cancer but have also resulted in untoward side effects associated with treatment. One such complication that has become increasingly recognized is the development of cardiomyopathy and heart failure. Whether a previously healthy person from a cardiovascular perspective develops cancer therapy–related cardiac dysfunction or a high-risk cardiovascular patient requires cancer therapy, the team of oncologists and cardiologists must be better equipped with an evidence-based approach to care for these patients across the spectrum. Although the toxicities associated with various cancer therapies are well recognized, limitations to our understanding of the appropriate course of action remain. In this first of a 2-part review, we discuss the epidemiologic, pathophysiologic, risk factors, and imaging aspects of cancer therapy–related cardiac dysfunction and heart failure. In a subsequent second part, we discuss the prevention and treatment aspects, concluding with a section on evidence gap and future directions. We focus on adult patients in all stages of cancer therapy from pretreatment surveillance, to ongoing therapy, and long-term follow-up. (Circ Heart Fail. 2016;9:e002661. DOI: 10.1161/CIRCHEARTFAILURE.115.002661.)

Key Words: anthracyclines ■ cardiomyopathies ■ cardiotoxicity ■ chemotherapy ■ heart failure ■ trastuzumab ■ ventricular dysfunction, left

Early detection and treatment has transformed cancer from a uniformly fatal disease to one that in many cases is a chronic condition. Improved survival, however, is often accompanied by treatment-related complications, including adverse effects of cancer therapies on the heart. In the long term, the risk of death from cardiovascular causes exceeds that of tumor recurrence for many forms of cancer.1,2 Patnaik et al3 found that cardiovascular disease (CVD) was the leading cause of death among older female breast cancer survivors without an initial diagnosis of CVD. Risk of toxicity was increased in patients with advanced age, multiple comorbid conditions, and in those requiring prolonged or intensive treatment. Cancer therapies including cytotoxic chemotherapy, molecular targeted therapies, and mediastinal irradiation have been linked to myocyte damage, left ventricular dysfunction (LVD), heart failure (HF), thrombogenesis, pericardial pathology, hypertension, ischemia, conduction and rhythm disturbances, and vasospasm.4,5 HF as a result of cancer therapy has been linked to a 3.5-fold increased mortality risk compared with idiopathic cardiomyopathy6 In part 1 of this 2-part review, we describe the definitions, pathophysiology, risk factors, and imaging aspects relevant to cancer therapy–related cardiac dysfunction.

Definitions
Several definitions of cancer therapy–related cardiac dysfunction have been proposed, making development of uniformly accepted recommendations for diagnosis, surveillance, and treatment challenging. The National Cancer Institute broadly defines cardiotoxicity as toxicity that affects the heart and proposes the Common Terminology Criteria for Adverse Events that defines LVD and HF based on severity into grades...
1 to 5. Grade 1 is defined as asymptomatic elevations in biomarkers or abnormalities on imaging. Grades 2 and 3 consist of symptoms with mild and moderate exertions. Grade 4 includes severe, life threatening symptoms requiring hemodynamic support, and grade 5 involves death. The Food and Drug Administration defines anthracycline cardiotoxicity as >20% decrease in left ventricular ejection fraction (LVEF) when baseline LVEF is normal, or >10% decrease when baseline LVEF is not normal.

The Cardiac Review and Evaluation Committee supervising trastuzumab trials defines cardiotoxicity as a decrease in LVEF that is either global or more severe in the septum and decline in LVEF of at least 5% to <55% with accompanying signs or symptoms of HF, or a decline of at least 10% to <55% without HF signs or symptoms. Several trials have specified toxicity with different parameters making estimation of the prevalence of cardiac toxicity difficult. In the Herceptin Adjuvant (HERA) trial, definitions of asymptomatic LVEF reductions were different and included decrease by ≥10% from baseline to an LVEF <50%, and HF as above accompanied by symptoms. The Breast Cancer International Research Group (BCIRG) used >10% reduction from baseline LVEF assessment to define asymptomatic LVD. An expert consensus published by the American Society of Echocardiography and European Association of Cardiovascular Imaging, comprised several well-respected cardiologists and oncologists within the field of cardio-oncology, defines cancer therapeutics–related cardiac dysfunction as a decrease in the LVEF of >10%, to a value <53% confirmed by repeat imaging. Further characterization is based on the presence or absence of symptoms. These definitions include arbitrary cutoffs without taking into account baseline risk and are not guided by clinical outcomes. In addition, LVEF-based definition has limitations including variable reproducibility, and the fact that many patients with HF have preserved LVEF. A more comprehensive definition for diagnosis of cancer therapy–related cardiotoxicity should take into account other imaging and biomarker based abnormalities as well.

**Classification**

Several attempts have been made to classify cardiotoxicity. Ewer and Lippman proposed cardiotoxicity based on the type and extent of structural abnormalities and degree of reversibility. Type I is irreversible and dose related with myocyte injury, whereas type II includes reversibility with cessation of treatment, lack of dose-relationship, and absence of ultrastructural abnormalities. Although intuitive, with anthracyclines as an example of type I and trastuzumab of type II cardiotoxicity, subsequent studies have raised concerns. This classification does not reflect the reality that anthracyclines and trastuzumab are rarely administered as sole agents and are usually shortly preceded or followed with drugs belonging to other classes. Hence, it is likely that the final cardiotoxic effect results from a synergic/combined action. Although anthracyclines and trastuzumab are different in their mechanisms of cardiotoxicity, early recognition and initiation of neurohormonal antagonists may reverse LVD in both cases.

Trastuzumab cardiotoxicity may be associated with troponin elevation and is not always reversible. Therefore, it is more appropriate to understand the biological mechanisms of cardiotoxicity and the clinical features at different stages of presentation.

**Pathophysiology and Epidemiology**

**Anthracyclines**

Anthracyclines (eg, doxorubicin, daunorubicin, epirubicin, and idarubicin) are a class of highly effective chemotherapy agents used for the treatment of many solid and hematologic cancers. In breast cancer, doxorubicin and epirubicin are used in both the neoadjuvant (before definitive surgery) and adjuvant (following definitive surgery) setting, as well as in metastatic patients. The mechanisms of action of anthracyclines include intercalation into nuclear DNA to impair protein synthesis, production of reactive oxygen species, and inhibition of topoisomerase II to inhibit DNA repair. Topoisomerase, an enzyme involved in DNA transcription and replication, is a known target of anthracyclines.

There are 2 isozymes of topoisomerase, Top 2-α, expressed in rapidly dividing cells, and Top 2-β, expressed in quiescent cells such as cardiac myocytes. The cardiac toxicity of anthracyclines is thought to be mediated through the binding of these agents to DNA and Top 2-β in cardiac myocytes, resulting in a complex formation that ultimately culminates in cell death (Figure). Older studies suggest an association between cumulative dosing and cardiotoxicity, with diastolic dysfunction reported at doses of 200 mg/m² of doxorubicin and systolic dysfunction at 400 to 600 mg/m². This has been challenged in recent literature suggesting that LVD can occur at any dose as evidenced in 18.9% of patients receiving a doxorubicin dose of 240 mg/m² in combination with cyclophosphamide. Factors increasing the risk of anthracycline toxicity include the presence of other CVD risk factors, associated therapies like mediastinal irradiation, and concomitant therapy with agents such as cyclophosphamide, paclitaxel, and trastuzumab. Anthracycline toxicity may be acute, sub-acute, or chronic. Acute toxicity is uncommon (≈1%) and generally reversible, whereas early-onset chronic progressive toxicity (1.6–2.1%) developing during treatment and late-onset chronic progressive types (1.6–5%) are more likely to be irreversible. This classification has been challenged as possible evolution of one phenomenon being clinically identified at various stages.

**Alkylating Agents**

Alkylating agents (eg, cyclophosphamide, ifosfamide, and melphalan) inhibit DNA transcription, thereby affecting protein synthesis. Agents such as cyclophosphamide have been associated with development of LVD in 7% to 28% of patients and may be dose related (≥150 mg/kg and 1.5 g/m² per day), occurring shortly after initial administration. LVD has also been observed with ifosfamide at doses that exceed 12.5 g/m².

**Microtubular Polymerization Inhibitors**

Taxanes (eg, paclitaxel and docetaxel) bind to and inhibit disassembly of microtubules, interrupting cell division. Taxanes interfere with the metabolism and excretion of anthracyclines and may potentiate LVD risk, particularly with high-dose anthracycline use. HF incidence with these agents is relatively low, with a reported 1.6% versus 0.7% incidence in patients.
with anthracycline-containing versus anthracycline-sparing regimens. Slower infusion or increasing intervals between paclitaxel and doxorubicin may attenuate toxicity. Newer adjuvant protocols and formulations might decrease the likelihood of toxicity.

HER2-Targeted Cancer Therapies

Overexpression of human epidermal growth factor receptor 2 (HER2/Erbb2) in breast cancer is a poor prognostic indicator, as these tumors tend to be more aggressive and associated with higher reoccurrence rates. Trastuzumab, a humanized anti-HER2 monoclonal antibody targeting the extracellular domain of this oncoprotein, has been shown in both the metastatic and adjuvant setting to dramatically change the survival in HER2 positive breast cancer. HER2/Erbb2 is expressed on myocytes and plays a protective role against myocardial stress. The binding of cancer drugs to HER2 receptor may disrupt this cardioprotective pathway and result in cardiotoxicity. Trials with trastuzumab observed increased incidence of LVD and its use with anthracyclines potentiate cardiotoxicity risk. Previous trials in the adjuvant setting reported HF in 1.7% to 4.1% and LVD in 7.1% to 18.6% of patients receiving trastuzumab, although in practice, incidence may be higher. Lapatinib, an oral tyrosine kinase inhibitor of HER2 and epidermal growth factor receptor, is approved in the metastatic setting and pertuzumab, a monoclonal antibody that blocks the dimerization of HER2 with other HER2 receptors, is approved in both the neoadjuvant and metastatic setting in combination with trastuzumab and docetaxel. Combination treatment using 2 anti-HER2 agents improves rates of pathologic complete responses in the neoadjuvant setting and survival in the metastatic settings, with comparable cardiotoxicity. Trastuzumab emtansine is a HER2-targeted antibody drug conjugate combining trastuzumab with a cytotoxic agent DM1, reported a 2.7% incidence of LVD. As the available treatments expand, new questions arise with respect to the development of cardiotoxicity.
VEGF Inhibitors (Monoclonal Antibodies and Small Molecules, Eg, Tyrosine Kinase Inhibitors)

Vascular endothelial growth factor (VEGF) inhibitors exert their action by inhibiting VEGF-mediated angiogenesis through various mechanisms. Small molecule tyrosine kinase inhibitors (sunitinib and sorafenib) are nonselective inhibitors of VEGF receptors, inhibiting up to 50 different kinases in addition to their intended target, thus, producing unwanted effects. These agents have been linked to hypertension, ischemia, LVD, and HF. Initial reports of sunitinib showed a 10% incidence of LVD but with recovery upon completion of therapy, and a 1.5% to 4.1% incident of HF. The real world experience is in fact worse, with >10% decline in ejection fraction. Bevacizumab is a monoclonal antibody that targets VEGF and is associated with a 5-fold increase in HF risk.

Radiotherapy

Radiation-induced heart disease is well recognized and may manifest years after exposure. Radiotherapy is associated with macrovascular, microvascular, and endothelial injury; valvular dysfunction; atherosclerosis; fibrosis; and pericardial disease. LVD and HF can occur as acute radiation myocardiitis but more commonly develops as a long-term consequence of fibrosis leading to ventricular dysfunction or restrictive cardiomyopathy. The presence of other CVD risk factors, concomitant anthracycline use, and anterior or left chest irradiation all increase risk. Mediastinal irradiation increases CVD and HF risk even 40 years after initial exposure. In a recent study of patients receiving radiation, there was a linear increase in coronary events with radiation dose. Events occurred 5 years after initial exposure and continued through the third decade following exposure.

Risk Factors

Identification of patients at risk is difficult though important. Patient-related risk factors include those with preexisting cardiac risk factors such as hypertension, diabetes mellitus, smoking, previous LVD or HF, coronary disease, increasing age, female gender, and postmenopausal status. Genetic polymorphisms may predispose to cardiotoxicity at lower anthracycline dose, suggesting that genetic variation might modulate the risk of cardiovascular toxicity after cancer treatment. In an unselected group of cancer patients, even before chemotherapy, the presence of N-terminal pro-brain natriuretic peptide, mid-regional pro-atrial natriuretic peptide, mid-regional pro-adenomedullin, high-sensitivity troponin T, and copeptin were associated with all-cause mortality. Therapy-related risk factors include use of combination cancer therapy, particularly if administered simultaneously, or as bolus, addition of mediastinal irradiation, and higher doses. Certain agents, such as anthracycline, trastuzumab, and cyclophosphamide, carry higher risk while others, such as bevacizumab, etoposide, and lapatinib, carry lower risk. Prior treatment with anthracyclines increases the risk if a patient presents with recurrent disease or a new malignancy requiring further anthracycline therapy.

Risk Prediction

Several risk scores have been published, although there is no consensus model. Herrmann et al proposed a risk model including both cancer therapy and patient factors. Romond et al used a model including age and baseline LVEF to estimate HF risk, also reporting LVEF recovery. Dranitsaris et al developed and tested a cycle-based risk-prediction tool in metastatic breast cancer patients receiving doxorubicin or its pegylated liposomal form. This score included age, weight, anthracycline exposure, and performance status, adding points for each additional chemotherapy cycle. Ezaz et al developed a 7-point risk score for 3-year HF risk after trastuzumab therapy in older females. Risk factors such as coronary disease, atrial fibrillation, hypertension, diabetes mellitus, and renal failure all portended higher risk. HF incidence was higher than previously reported, with the oldest patients approaching 45% incidence (Table 1).

Biomarkers

A biomarker approach for early identification, risk stratification, and monitoring of chemotherapy-related cardiotoxicity holds promise, although challenges exist with respect to timing of measurement, optimal assays, and whether this strategy is best used alone or in conjunction with imaging.

Biomarker of Injury (Eg, Troponin)

Troponin levels can be monitored before and after each therapy cycle and serve as a predictor of future cardiac dysfunction. A

Table 1. Overview of Validated Risk-Prediction Models

<table>
<thead>
<tr>
<th>Reference</th>
<th>Population</th>
<th>Risk Factors</th>
<th>n</th>
<th>Definition of Cardiotoxicity</th>
<th>Discrimination</th>
<th>Calibration</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ezaz et al</td>
<td>Women with early-stage breast cancer who underwent surgery and adjuvant trastuzumab therapy</td>
<td>Adjuvant therapy type, Age, CAD, AF, DM, HTN, renal failure</td>
<td>1664</td>
<td>ICD-9CM code for HF or CM that seems in at least 1 inpatient claim or 2 outpatient claims at least 30 d apart</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Romond et al</td>
<td>Women with HER2+ breast cancer</td>
<td>Age, baseline LVEF</td>
<td>1830</td>
<td>LVEF drop &gt;10% from baseline to &lt;55% or drop &gt;5% to level below lower limit of normal</td>
<td>0.72 (0.70 after bootstrapping)</td>
<td>NR</td>
<td>Bootstrapping</td>
</tr>
<tr>
<td>Dranitsaris et al</td>
<td>Women with metastatic breast cancer receiving anthracycline-based chemotherapy</td>
<td>Age, weight, baseline anthracycline exposure, performance status, no. of cycles</td>
<td>509</td>
<td>(1) LVEF drop 20% but still normal range, (2) LVEF drop 10% if abnormal, (3) signs/symptoms HF</td>
<td>0.84</td>
<td>NR</td>
<td>Bootstrapping</td>
</tr>
</tbody>
</table>

AF indicates atrial fibrillation; CAD, coronary artery disease; CM, cardiomyopathy; DM, diabetes mellitus; HF, heart failure; HTN, hypertension; LVEF, left ventricular ejection fraction NR, not reported.
high negative predictive value with absence of troponin elevation has been reported in patients receiving high-dose anthracyclines. Early increase in troponin I after anthracycline use predicted diastolic dysfunction in 34% of patients. Increased troponin I in patients receiving trastuzumab had a decreased likelihood of LVEF recovery and a higher incidence of cardiac events. Troponin I levels at completion of anthracycline treatment were predictive of subsequent reduction in LVEF and cardiac events. Smaller studies have looked at troponin use for identification of at-risk patients with newer agents, such as anti-VEGF monoclonal antibodies, anti-VEGFR tyrosine kinase inhibitors, and a kinesin inhibitor.

Biomarker of Load (E.g., Natriuretic Peptide)
Natriuretic peptides have been studied in chemotherapy-treated patients with variable results. In one study, brain natriuretic peptide was predictive of LVD at 3-, 6-, and 12-month follow-up. In patients undergoing doxorubicin therapy, an increase in natriuretic peptides during the first 90 days was predictive of LVD at 4 years. Several studies, however, have failed to show an association between these biomarkers and cardiac dysfunction, and they may be more useful for their negative predictive value as part of a surveillance strategy. Further studies are needed to understand the role of natriuretic peptide use in this population and to understand the differences in the various types of natriuretic peptides.

Other Biomarkers
High-sensitivity C-reactive protein predicts cardiotoxicity in patients treated with trastuzumab. Other studies of patients receiving anthracycline-containing regimen followed by taxanes and trastuzumab showed no association between C-reactive protein, galectin-3, ST-2 or growth differentiation factor 15, and cardiotoxicity but 1 study reported that changes in myeloperoxidase levels were associated with cardiotoxicity. In a recent study of multiple biomarkers, myeloperoxidase levels rose early, persisted throughout the course of therapy, and were associated with cardiotoxicity (Table 2).

Imaging
Echocardiography
Two-Dimensional Echocardiography
Because of its widespread availability and safety, 2-dimensional echocardiography (2DE) is increasingly used in monitoring patients with cancer. 2DE allows for characterization of systolic and diastolic function, pulmonary pressures, valvular function, right ventricular (RV) function, and the pericardium. Assessment of LVEF is based on assumptions of cardiac geometry, depends on image quality, cannot detect small regional alterations in myocardial function, and may vary based on loading conditions. The American Society of Echocardiography suggests the addition of contrast to 2DE for better definition of endocardial borders in patients with breast implants or mastectomy. One of the drawbacks of 2DE is its inability to detect small (<10%) changes in LVEF, a limitation in patients with cancer in whom subtle differences in cardiac function may have important implications on treatment dose adjustment or cessation.

Three-Dimensional Echocardiography
Three-dimensional echocardiography increases the accuracy of detecting more subtle changes in LVEF, with a higher reproducibility. Thavendiranathan et al demonstrated that non-contrast three-dimensional echocardiography had the highest inter- and intraobserver reproducibility for LVEF and LV volume detection in sequential 1 year follow-up of patients receiving cancer therapy. Unlike with 2DE, the study of use of contrast in three-dimensional echocardiography has not been firmly established.

Diastolic Function
Diastolic dysfunction often precedes systolic dysfunction in patients receiving chemotherapy. Although findings have been inconsistent, changes in diastolic parameters, such as isovolumetric relaxation and deceleration time, have been shown in patients as early as 3 months following doxorubicin and were predictive of systolic dysfunction at 6 months, with a sensitivity similar to strain imaging. Early reductions in early diastolic mitral inflow velocity and early diastolic mitral inflow velocity/late diastolic mitral inflow velocity ratio, or increase in early diastolic mitral inflow velocity/early diastolic mitral annular velocity, predict future decrement in systolic function years after chemotherapy. Still, the use of diastolic parameters to predict subsequent cancer-related cardiotoxicity remains unclear, given the variability based on loading conditions in patients with cancer.

Strain and Speckle Tracking
More recent techniques, including strain and speckle tracking may allow for earlier detection of more subtle changes in myocardial function. Strain imaging assesses myocardial function based on measurements of myocardial velocities in adjacent areas as they relate to distance between those areas during the cardiac cycle. Speckle tracking has largely replaced tissue Doppler imaging for analysis of myocardial deformation and holds promise in early prediction of chemotherapy cardiotoxicity. Global longitudinal strain reduction precedes LVD in patients who later develop HF. Strain abnormalities can be seen early despite preserved LVEF. Persistent abnormalities were found in patients receiving high-dose anthracyclines. In patients receiving trastuzumab alone or with anthracyclines, a change in global longitudinal strain of >11% was the strongest predictor of cardiotoxicity. This technique is limited by availability, image quality, variability of quantification between vendors, and lack of universal definitions. In addition to measuring linear deformation, speckle tracking can assess torsion, a newer parameter requiring further study in patients receiving anthracyclines.

Right Ventricular Function
Subclinical changes in RV systolic and diastolic parameters have been described early after anthracycline therapy and correlated with elevations in N-terminal pro-brain natriuretic peptide levels. RV involvement after chemotherapy has been noted in earlier studies involving RV myocardial biopsies, but frequency is not known. In patients receiving isolated left ventricular mechanical support in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), markers of RV dysfunction were more common and more
### Table 2. Role of Cardiac Biomarkers in Chemotherapy-Induced Cardiotoxicity

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient Population</th>
<th>N</th>
<th>Chemotherapy</th>
<th>Biomarker</th>
<th>Value Cutoff</th>
<th>Timing of Measurement</th>
<th>Results</th>
</tr>
</thead>
</table>
| Ky et al65         | HER2+ breast cancer | 78    | Doxorubicin, cyclophosphamide, paclitaxel, trastuzumab | TnI, cTNI NT-proBNP  
GDF-15, MPO  
PIGF, sFlt-1  
gal-3 | 100 pg/mL | Biomarkers measured at baseline, 3, and 6 mo | LVEF measured at baseline, 3, 6, 9, 12, and 15 mo | TnI and MPO rise at 3 mo was associated with subsequent cardiotoxicity |
| Skovgaard et al67  | Breast cancer, hematologic malignancies, uterine/ovarian cancer | 333   | Anthracycline | BNP | No standard interval of measurements | | BNP and LVEF independently predicted CHF  
Only BNP was associated with overall mortality |
| Sawaya et al69     | HER2+ breast cancer | 81    | Anthracycline, paclitaxel, trastuzumab | Troponin NT-proBNP ST-2 | ≥30 pg/mL  
>125 pg/mL  
>35 pg/mL | Baseline, 3, 6, 9, 12, and 15 mo | Elevated TnI at 3 mo was predictive of subsequent cardiotoxicity  
No change in NT-proBNP and ST-2 |
| Lipshultz et al72   | Children with high-risk ALL | 156   | Doxorubicin | TnT NT-proBNP hs-cTNI | Any detectable amount  
≥150 pm/ml, age<1;  
≥100 pm/ml, age>1  
≥1.9 mg/L | Biomarkers measured at baseline, days 1–7 of doxorubicin induction, 7 days after a doxorubicin dose, and at end of doxorubicin therapy | LVEF measured at baseline, after therapy, and every 2 y thereafter |
| Ontilt et al80      | HER2+ breast cancer | 54    | Trastuzumab adjuvant | BNP hs-cTNI TnI | ≥200 pg/mL  
≥3 mg/mL  
≥0.01 ng/mL | Biomarkers measured at baseline, every 3 wk up to 1 y | LVEF measured every 3–4 mo  
Only hs-cTNI was associated with increased risk for clinically significant decline in LVEF |
| Morris et al83      | HER2+ breast cancer | 95    | Doxorubicin, cyclophosphamide, paclitaxel, lapatinib | TnI cTNI | >0.04 ng/mL (DF/HCC)  
>0.08 ng/mL (MSKCC)  
≥0.8 mg/dL (MSKCC)  
≥0.3 mg/dL (DF/HCC) | Biomarker measured every 2 wk during chemo, 6,9, and 18 mo  
LVEF measured at months 0,6,9, and 18 mo | TnI rise (peaking at ≤14 wk) preceded maximal decline in LVEF but no relation to max LVEF decline  
CRP did not correlate with LVEF decline |
| Romano et al81      | Breast cancer | 92    | Anthracycline, taxane, 5-fluorouracil, cyclophosphamide | NT-proBNP TnI | >153 pg/mL, age ≤50;  
222 pg/mL, age >50  
<5 ng/mL, age <50  
<0.08 ng/mL, age ≥50 | Biomarkers measured at baseline, before, and 24 h after each drug administration  
LVEF measured at baseline, every 2 cycles, end of chemo, 3, 6, and 12 mo follow-up | TnI-proBNP was predictive of LVEF impairment at 3, 6, and 12 mo follow-up |
| Cardinale et al83   | Breast cancer | 251   | Trastuzumab, anthracycline, cyclophosphamide, paclitaxel | TnI | >0.08 pg/mL | Biomarker measured before and after each cycle | LVEF measured at baseline, every 3 mo during therapy and every 6 mo after |
| Mavinkurve-Grootthus et al84 | Various pediatric cancers | 122   | Anthracycline-containing regimen | NT-proBNP TnT | >10 pmol/L, male; >18 pmol/L, female  
>0.1 ng/mL | Measured once | Elevated NT-proBNP was associated with cumulative anthracycline dose |
| Dodos et al85       | Solid or hematological malignancy | 100   | Anthracycline-containing regimen | TnT NT-proBNP | >0.01 ng/mL  
<153 pg/mL, female, age <50;  
<334 pg/mL, female, age 50–70;  
<18 pg/mL, male, age <50;  
<227 pg/mL, male, age 50–70 | Measured 24–72 h, 1, 6, and 12 mo after last course of chemo | TnI and proBNP did not predict cardiac dysfunction |
| Jingu et al81       | Eosophageal cancer | 197   | Radiotherapy | BNP | Measured before, <1 mo, 1–2, 3–8, 9–24, 24 h after radiotherapy | BNP higher in patients who had high FDG accumulation  
Increase in TnI as early as first cycle predicted subsequent LVEF decline |
| Sandri et al86      | Various | 179   | Various regimens including epirubicin, cyclophosphamide, taxotere, carboplatin | TnI | >0.08 ng/mL | Biomarkers measured at baseline, end of infusion, 12, 24, 36, 72 h after each cycle  
LVEF measured at baseline, L, 3, 4, 7, and 12 mo after end of treatment | LVEF measured at baseline, 3, 6, 9, 12, and 15 mo  
No change in NT-proBNP and ST-2 |
| Cardinale et al86   | Breast cancer, ovarian cancer, small-cell lung cancer, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma | 204   | Various regimens including epirubicin, cyclophosphamide, taxotere, carboplatin | TnI CK CK-MB | >0.5 ng/mL  
>100 IU/L  
>5 ng/mL | Before, immediately after, and then 12, 24, 36, and 72 h after every cycle of chemo | TnI elevation predicted future LVEF decline |

Studies ordered by date with sample size ≥50 patients. ALL indicates acute lymphoblastic leukemia; CHF, congestive heart failure; CK, creatinine kinase; CK-MB, creatinine kinase, MB fraction; CRP, C-reactive protein; DF/HCC, Dana Farber/Harvard Cancer Center; FDG, fluodeoxyglucose; gal-3, galactin 3; GDF-15, growth differentiation factor 15; HER2+, human epidermal growth factor receptor 2; LVEF, left ventricular ejection fraction; MPO, myeloperoxidase; MSKCC, Memorial Sloan-Kettering Cancer Center; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PIGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase receptor 1; ST-2, interleukin family member; TnI, troponin Ic,
severe in chemotherapy-induced cardiotoxicity compared with ischemic or nonischemic cardiomyopathy. These included higher levels of transaminases, lower systolic pulmonary pressures, moderate tricuspid regurgitation, and higher ratios of central venous to pulmonary capillary wedge pressures. Echocardiographic assessment of the RV should involve careful attention to chamber size, tricuspid annular plane systolic excursion, estimation of pulmonary artery systolic pressure, and RV diastolic parameters. Areas of future interest include usage of speckle tracking for more in depth understanding of chemotherapy-related RV involvement.

Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging (CMR) is the gold standard for detection of ventricular volumes and function. CMR has a greater intra- and interobserver reproducibility than echocardiography and may identify a higher prevalence of cardiomyopathy compared with echocardiography in patients with cancer. CMR affords the opportunity for noninvasive tissue characterization including myocardial edema, inflammation, and fibrosis, thus, playing an important role in identification of early and late cardiotoxicity in patients with cancer. Early increases in pre- and postcontrast signal intensity may predict reductions in LVEF at 28 days and 6 months. Subependymal delayed enhancement with gadolinium has been noted in the lateral wall of trastuzumab-treated patients who developed cardiomyopathy; however, studies on delayed enhancement have demonstrated mixed results. CMR may also have prognostic value in detection of late cardiotoxicity. LV mass index has been shown to be an independent predictor of major adverse cardiac events in cancer patients with cardiomyopathy following treatment with anthracyclines. Larger patient cohorts require study to further define the role of CMR in the prediction of cardiotoxicity. As with use of CMR in the general cardiac population, higher cost, lack of universal availability, and patient-related factors, such as pacemakers and claustrophobia, limit its widespread use, though it plays an important role particularly in patients with technical limitations to echocardiography.

Radionuclide Imaging
Multiple-gated acquisition used to be the mainstay for cardiac functional assessment in patients with cancer because of high reproducibility and availability; however, these advantages are now limited because of changes in equipment and technique. Other limitations include the inability to obtain other structural and functional information, which can be obtained by echocardiogram. Multiple-gated acquisition relies on ejection fraction being the most appropriate parameter to measure, at a higher cost compared with echocardiography. The largest disadvantage of multiple-gated acquisition is radiation exposure, which must be weighed against necessity on an individual basis when other options are available.

Positron Emission Tomography/Magnetic Resonance
Positron emission tomography/magnetic resonance is an emerging modality, though currently largely limited to research algorithms. In the assessment of cardiomyopathy, positron emission tomography allows for the determination of myocardial perfusion and glucose metabolism. Furthermore, positron emission tomography/magnetic resonance allows for the evaluation of myocardial viability. The combined use of positron emission tomography/magnetic resonance allows not only for the acquisition of complimentary data on cardiac structure and function but also limits exposure to radiation. This is an important advantage when imaging patients with cancer, who may have already been exposed to large amounts of radiation.

Conclusion
Cancer therapy–related cardiotoxicity has become a topic of growing concern. Early toxicity can limit a patient’s ability to complete effective cancer therapy. Late-onset toxicity impacts cardiac mortality among cancer survivors. This complex population of patients presents unique challenges to clinical care. Overlaps in clinical symptomatology can make the delineation between symptoms of cardiac dysfunction and expected side effects of chemotherapy difficult. Additional barriers include a lack of a universal definition of cardiotoxicity as well as the absence of established guidelines for monitoring and surveillance. Certain biomarkers and novel imaging techniques have been investigated, but further study is necessary to clarify and optimize their role in routine clinical practice. Enhanced recognition and awareness of this unique patient population, and more universally accepted definitions of cancer-related cardiotoxicities, will allow advancement in the field of cardio-oncology.

Disclosures
Dr Bloom is a consultant for Bristol Myers Squibb. Dr Ky is supported by NIH K23 HL095661 and R01 HL118018 and has an investigator-initiated research grant from Pfizer, Inc. Dr Nohria is a consultant for Vertex Pharmaceuticals. Dr Gheorghiade reports consulting relationships with Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, Cardiorentis Ltd, CorThera, Cytokinetica, CytoPhex Inc, Debiopharm SA, Errekappa Therapeutici, GlaxoSmithKline, Ikaria, Intersection Medical Inc, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Ono Pharmaceuticals USA, Osaka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, sanofi-aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals North America Inc, and Trevena Therapeutics. Dr Butler reports receiving research support from the National Institutes of Health and European Union, and serve as a consultant to Amgen, Bayer, Cardiocell, Celladon, Novartis, Trevena, Relypsa, Z Pharma, and Zensun. The other authors report no conflict of interest.

References


Bloom et al.  Cancer Therapy–Related Heart Failure


Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging
Michelle W. Bloom, Carine E. Hamo, Daniela Cardinale, Bonnie Ky, Anju Nohria, Lea Baer, Hal Skopicki, Daniel J. Lenihan, Mihai Gheorghiade, Alexander R. Lyon and Javed Butler

Circ Heart Fail. 2016;9:e002661
doi: 10.1161/CIRCHEARTFAILURE.115.002661
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/9/1/e002661

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/